Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Xiangnan Qiang"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fb8ee21c280b48fd9bb8f6009049ba85
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d979c39b1ede4b15a3fd48b374be2423
Autor:
Panpan Wang, Jingjing Wang, Yawen Zhang, Xiangnan Qiang, Qingyang Gu, Ting Ni, Tongxin Huo, Huacheng He, Wenting Shi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a10e64b2cdc843809ef31f67a1150eb7
Autor:
Jun Huang, Ronghua Zhang, Xiangnan Qiang, Zhixiang Zhang, Ting Ni, Chenhui He, Zhifeng Zhao, Jingwei Huang, Xiangyi Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2a7e50b52a784bb4911d3cc8743893bb
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/294ef8b56b764258b1e2b5aeecd6cc9c
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/bca173176e234f08a5f4873566b7e6da
Publikováno v:
Cancer Research. 83:3971-3971
Human cancer cell lines have long been applied for anti-tumor drug discovery considering their acquired genomic diversity of different carcinomas. Genetic engineering based on cancer cell lines is no doubt a useful and promising approach in induction
Publikováno v:
Cancer Research. 83:4988-4988
Mutant BRAF, one of the most frequently mutated serine/threonine kinase, drives tumorigenesis via activating MAPK signaling across various tumor types. Expanded genomic and mechanistic studies over the past two decades have revealed the heterogeneity
Autor:
Shaoyu Yan, Xiangnan Qiang, Xuzhen Tang, Xiaoran Qin, Qunsheng Ji, Xianzhi Zhai, Jie Xu, Fuyang Wang, Hui Qi, Li Yang, Qingyang Gu
Publikováno v:
Cancer Research. 79:1055-1055
Tyrosine Kinase Inhibitor (TKI) of Epidermal Growth Factor Receptor (EGFR) is a first-line therapy for non-small cell carcinoma lung cancer patients with EGFR mutations, but patients often develop resistance to such a target therapy. Recently several
Autor:
Norman Zhang, Qunsheng Ji, Yuxin Qin, Shuqun Yang, Yunbiao Yan, Qingyang Gu, Baoyuan Zhang, Xiangnan Qiang, Hua Dong, Xuzhen Tang, Zhixiang Zhang
Publikováno v:
Cancer Research. 76:82-82
Introduction: Large efforts have been made to detect somatic alterations and corresponding transcriptome changes in cancer patients, which are expected to bring about significant improvements in precision cancer medicine. Here we report a comprehensi